82594-80-7

Basic information

• Product Name: 1-Triphenylmethyl-4-methylimidazole
• Synonyms: 1-triphenylmethyl-4-methylimidazole;4-Methyl-1-tritylimidazole;4-methyl-1-trityl-1h-imidazole
• CAS NO: 82594-80-7
• Molecular Formula: C₂₃H₂₀N₂
• Molecular Weight: 324.42
• Mol File: 82594-80-7.mol
• Article Data: 20

Chemical Properties

• Boiling Point: 466.5 °C at 760 mmHg
• Flash Point: 236 °C
• Appearance: /
• Density: 1.05
• Vapor Pressure: 1.96E-08mmHg at 25°C
• Refractive Index: 1.6
• CAS DataBase Reference: 1-Triphenylmethyl-4-methylimidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Triphenylmethyl-4-methylimidazole(82594-80-7)
• EPA Substance Registry System: 1-Triphenylmethyl-4-methylimidazole(82594-80-7)

Safety Data

• Hazardous Substances Data: 82594-80-7(Hazardous Substances Data)

Usage

General Description

1-Triphenylmethyl-4-methylimidazole, also known as "tritylimidazole", is a chemical compound with the molecular formula C23H20N2. It is a derivative of imidazole and triphenylmethyl, and is used in organic synthesis as a protecting group for alcohols and carboxylic acids. 1-Triphenylmethyl-4-methylimidazole is known for its ability to form stable complexes with various metal ions, making it useful in catalysis and coordination chemistry. Tritylimidazole is also used as a reagent in the synthesis of pharmaceuticals and other organic compounds, and it has been studied for its potential applications in advanced materials and biochemistry.

InChI:InChI=1/C23H20N2/c1-19-17-25(18-24-19)23(20-11-5-2-6-12-20,21-13-7-3-8-14-21)22-15-9-4-10-16-22/h2-18H,1H3

Upstream product

• 822-36-6 4-methyl-1H-imidazole 
• 76-83-5 trityl chloride 

Downstream Products

• 5213-35-4 4-methyl-2-nitroimidazole 
• 115383-28-3 4-methyl-3-phenacyl-1-triphenylmethylimidazolium bromide 
• 211488-49-2 1-(4-Methyl-1-trityl-1H-imidazol-2-yl)-2-trityloxy-ethanol 
• 869967-21-5 4-methyl-1-(triphenylmethyl)-1H-imidazole-2-carbaldehyde 
• 863399-36-4 4-methyl-1-(triphenylmethyl)-1H-imidazole-2-methanol 
• 144748-27-6 1-propyl-5-methylimidazole 
• 1070654-62-4 1-trityl-3-[3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propyl]-4-methyl-1H-imidazol-3-ium bromide 
• 1072452-34-6 1-trityl-3-[4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)butyl]-4-methyl-1H-imidazol-3-ium bromide 

Relevant articles and documents

1,(3,)5-substituted imidazoles, useful in the treatment of hypertension and methods for their preparation

The present invention provides novel 1,5 and 1,3,5-substituted imidazole compounds in hydrophilic or lipophilic form, which are useful as angiotensin II ATI receptor antagonists suitable for transdermal delivery. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing compounds and their use in methods of treating hypertension and cardiovascular diseases.

LRRK2 INHIBITORS

Provided herein are compounds that inhibit or partially inhibit the activity of leucine rich repeat kinases. Also provided herein are methods of treatment of CNS disorders comprising administration of inhibitors of leucine rich repeat kinases.

Synthesis, Biological Evaluation, and Molecular Modeling of 1 -Benzyl-1H-imidazoles as Selective Inhibitors of Aldosterone Synthase (CYP11B2)

Reducing aldosterone action is beneficial in various major diseases such as heart failure. Currently, this is achieved, with mineralocorticoid, receptor antagonists, however, aldosterone synthase (CYP 11B2) inhibitors may offer a promising alternative. In this study, we used three-dimensional modeling of CYP11B2 to model, the binding modes of the natural substrate 18-hydroxycorticosterone and the recently published CYP11B2 inhibitor R-fadrozole as a rational guide to design 44 structurally simple and achiral 1-benzyl-1H-imidazoles. Their syntheses, in vitro inhibitor potencies, and in silico docking are described. Some promising CYP11B2 inhibitors were identified, with our novel lead, MOERAS 115 (4-((5-phenyl-1H-imidazol-1-yl)methyl) benzonitrile) displaying an IC50 for CYP11B2 of 1.7 nM, and a CYP11B2 (versus CYP11B1) selectivity of 16.5, comparable to R-fadrozole (IC 50 for CYP11B26.0 nM, selectivity 19.8). Molecular docking of the inhibitors in the models enabled us to generate posthoc hypotheses on their binding modes, providing a valuable basis for future studies and further design of CYP11B2 inhibitors.